Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...